Expression of canine interferon-γ by a recombinant vaccinia virus and its antiviral effect

Virus Research

Volumn 75, Issue 2, 2001, Pages 113-121

  Nishikawa, Yoshifumi ^a,b   Iwata, Akira ^c   Katsumata, Atsushi ^c   Xuan, Xuenan ^a   Nagasawa, Hideyuki ^a   Igarashi, Ikuo ^a   Fujisaki, Kozo ^a   Otsuka, Haruki ^b   Mikami, Takeshi ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE   (Japan)

Author keywords

Antiviral activity; Canine adenovirus type 1; Canine herpesvirus; Canine IFN ; Pseudorabies virus; Vaccinia virus

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; GROWTH INHIBITION; HERPES VIRUS; NONHUMAN; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; VACCINIA VIRUS; VIROGENESIS; VIRUS EXPRESSION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; GENETIC VECTORS; INTERFERON TYPE II; NEUTRALIZATION TESTS; RABBITS; RECOMBINATION, GENETIC; VACCINIA VIRUS;

EID: 0035025355     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(01)00223-4     Document Type: Article

References (39)

1. Alcami A., Smith G.L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:1995;4633-4639.
2. Balachandra K., Thawaranantha D., Ayuthaya P.I., Bhumisawasdi J., Shiraki K., Yamanishi K. Effects of human alpha, beta and gamma interferons on varicella zoster virus in vitro. Southeast Asian J. Trop. Med. Public Health. 25:1994;252-257.
3. Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology. 64:1988;1-9.
4. Buller R.M.L., Smith G.L., Cremer K., Notkins A.L., Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with thymidine kinase-negative phenotype. Nature. 317:1985;813-815.
5. Davies M.V., Chang H.-W., Jacobs B.L., Kaufman R.J. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67:1993;1688-1692.
6. Devos K., Duerinck F., Van Audenhove K., Fiers W. Cloning and expression of the canine interferon-γ gene. J. Interferon Res. 12:1992;95-102.
7. Domke-Opitz I., Straub P., Kirchner H. Effect of interferon on replication of herpes simplex virus types 1 and 2 in human macrophages. J. Virol. 60:1986;37-42.
8. Feducchi E., Alonso M.A., Carrasco L. Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J. Virol. 63:1989;1354-1359.
9. Fuller L., Fernandez J., Zheng S., Carreno M., Esquenazi V., Yang W.C., Miller J. Immunochemical and biochemical characterization of purified canine interferon-gamma. Production of a monoclonal antibody, affinity purification, and its effect on mixed lymphocyte culture and mixed lymphocyte kidney culture reactions. Transplantation. 53:1992;195-202.
10. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA. 91:1994;1198-1205.
11. Heise M.T., Virgin H.W. IV. The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections. J. Virol. 69:1995;904-909.
12. Iwata A., Mizukoshi-Iwata N., Saito T., Hamada K., Sokawa Y., Ueda S. Cytopathic effect inhibition assay for canine interferon activity. J. Vet. Med. Sci. 58:1996;23-27.
13. Kanno H., Hattori A., Sato H., Murata H., Huang F.H., Hayashi A., Suzuki N., Yamamoto I., Kawamoto S., Minami M., Miyatake S., Shuin T., Kaplittt M.G. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-γ Cancer Gene Ther. 6:1999;147-154.
14. Kit S., Kit M., Pirtle E.C. Attenuated properties of thymidine kinase-negative deletion mutant of pseudorabies virus. Am. J. Vet. Res. 46:1985;1359-1367.
15. Klavinskis L.S., Geckeler R., Oldstone M.B.A. Cytotoxic T lymphocyte control of acute lymphocytic choriomeningitis virus infection: interferon gamma, but not tumor necrosis factor alpha, displays antiviral activity in vivo. J. Gen. Virol. 70:1989;3317-3325.
16. Kohonen-Corish M.R., Blanden R.V., King N.J. Induction of cell surface expression of HLA antigens by human IFN-gamma encoded by recombinant vaccinia virus. J. Immunol. 143:1989;623-627.
17. Kohonen-Corish M.R., King N.J., Woodhams C.E., Ramshaw I.A. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. J. Immunol. 20:1990;157-161.
18. Leist T.P., Eppler M., Zinkernagel R.M. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice. J. Virol. 63:1989;2813-2819.
19. Lotz M., Tsoukas C.D., Fong S., Carson D.A., Vaughan J.H. Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma. Eur. J. Immunol. 15:1985;520-525.
20. Matheux F., Grand R.L., Rousseau V, Maeyer E.D., Dormont D., Lauret E. Macaque lymphocytes transduced by a constitutively expressed interferon gene display an enhanced resistance to SIVmac251 infection. Hum. Gene Ther. 10:1999;429-440.
21. Mistchenko A.S., Falcoff R. Recombinant human interferon-gamma inhibits adenovirus multiplication in vitro. J. Gen. Virol. 68:1987;941-944.
22. Mossman K., Upton C., Buller R.M., McFadden G. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology. 208:1995;762-769.
23. Motohashi T., Tajima M. Isolation of a herpesvirus from a diseased adult dog in Japan. Jpn. J. Vet. Sci. 28:1966;307-314.
24. Nemunaitis J., Bohart C., Fong T., Meyer W., Edelman G., Paulson R.S., Orr D., Jain V., O'Brien J., Kuhn J., Kowal K.J., Burkeholder S., Bruce J., Ognoskie N., Wynne D., Martineau D., Ando D. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 5:1998;292-300.
25. Nemunaitis J., Fong T., Burrows F., Bruce J., Peters G., Ognoskie N., Meyer W., Wynne D., Kerr R., Pippen J., Oldham F., Ando D. Phase I trial of interferon retroviral vector administrated intratumorally with multiple courses in patients with metastatic melanoma. Hum. Gene Ther. 10:1999;1289-1298.
26. Nishikawa Y., Iwata A., Xuan X., Nagasawa H., Fujisaki K., Otsuka H., Mikami T. Expression of canine interferon-γ by a recombinant vaccinia virus. FEBS Lett. 466:2000;179-182.
27. Peplinski G.R., Tsung K., Meko J.B., Norton J.A. Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses. Ann. Surg. Oncol. 3:1996;15-23.
28. Ramsey A.J., Ruby J., Ramshaw I.A. A case of cytokines as effector molecules in the resolution of virus infection. Immunol. Today. 14:1993;155-157.
29. Rodriguez M., Pavelko K., Coffman R.L. Gamma interferon is crucial for resistance to Theiler's virus-induced demyelination. J. Virol. 69:1995;7286-7290.
30. Schijns V.E., Van der Neut R., Haagmans B.L., Bar D.R., Schellekens H., Horzinek M.C. Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells. J. Gen. Virol. 72:1991;809-815.
31. Symons J.A., Alcami A., Smith G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species apecificity. Cell. 81:1995;551-560.
32. Tamura M., Asada H., Kondo K., Takahashi M., Yamanishi K. Effects of human and murine interferons against hemorrhagic fever with renal syndrome (HFRS) virus (Hantaan virus). Antiviral Res. 8:1987;171-178.
33. Taylor J.L., Little S.D., O'Brien W.J. The comparative anti-herpes simplex virus effects of human interferons. J. Interferon Cytokine Res. 18:1998;159-165.
34. Watanabe Y., Kuribayashi K., Miyatake S., Nishihara K., Nakayama E., Taniyama T., Sakata T. Exogenous expression of mouse interferon cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 86:1989;9456-9460.
35. Wheelock E.F. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science. 149:1965;310-311.
36. Wong G.H.W., Goeddel D.V. Tumor necrosis factor and inhibit virus replication and synergize with interferons. Nature. 323:1986;819-822.
37. Yasuda A, Kimura-Kuroda J., Ogimoto M., Miyamoto M., Sata T., Sato T., Takamura C., Kurata T., Kojima A., Yasui K. Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express preM and E glycoproteins of Japanese encephalitis virus. J. Virol. 64:1990;2788-2795.
38. Zhang X., Hinton D.R., Cua D.J., Stohlman S.A., Lai M.M. Expression of interferon-gamma by a coronavirus defective-interfering RNA vector and its effect on viral replication, spread, and pathogenicity. Virology. 233:1997;327-338.
39. Zucker K., Lu P., Esquenazi V., Miller J. Cloning of the cDNA for canine interferon-γ J. Interferon Res. 12:1992;191-194.